AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03788525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed recreational screen time
Description: Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
Study NCT01215409 — intervention group
Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: 5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
Study NCT03289156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arousal Reappraisal
Description: Brief readings educating about the stress response and usefulness of arousal reappraisal.
Study NCT03289156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arousal Reappraisal
Description: Brief readings educating about the stress response and usefulness of arousal reappraisal.
Study NCT03289156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
Study NCT03289156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
Study NCT04023409 — intervention group
Intervention type: OTHER
Intervention: NA: no intervention
Description: NA: no intervention
Study NCT01556009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib
Description: 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
Study NCT01556009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid %20 topical solution
Description: 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
Study NCT04734964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Exercise training session for 45 minutes.
Study NCT03227445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA placebo DPI
Description: ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
Study NCT03227445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS placebo DPI
Description: DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
Study NCT03227445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler placebo DPI
Description: HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
Study NCT03227445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler preference questionnaires
Description: Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
Study NCT02631629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified foods
Description: The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
Study NCT02631629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified foods
Description: The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
Study NCT04033445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo IV or SC.
Study NCT04033445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.
Study NCT03897088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PART 1: Double-blind Placebo-controlled
Description: all eligible subjects will receive either tildrakizumab or placebo
Study NCT03897088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PART 1: Double-blind Placebo-controlled
Description: all eligible subjects will receive either tildrakizumab or placebo
Study NCT03897088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PART 2: Double-blind Active Treatment Extension
Description: subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
Study NCT03348943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Right hemiparesis, right upper limb.
Description: Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
Study NCT03348943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right hemiparesis, left upper limb
Description: Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
Study NCT03348943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Left hemiparesis, left upper limb
Description: Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
Study NCT03348943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Left hemiparesis, right upper limb
Description: Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
Study NCT03784664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: arterial blood sample with puncture of the radial artery
Study NCT03784664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Veinous blood gas
Description: veinous blood sample using peripheral venepuncture
Study NCT02415023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib+paclitaxel
Description: 28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
Study NCT03787680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
Study NCT03787680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: 160 mg by mouth daily for days 1-7 of a 28-day cycle.
Study NCT04069637 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Growth-sparing instrumentation and titanium levels
Description: Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.4 mg/kg α-TEA
Description: Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0 mg/kg α-TEA
Description: Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.6 mg/kg α-TEA
Description: Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg/kg α-TEA
Description: Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19.2 mg/kg α-TEA
Description: Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 22.3 mg/kg α-TEA
Description: Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT02192346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 26.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study NCT03033420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
Description: A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
Study NCT01283919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study NCT01283919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study NCT04648358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
Study NCT04648358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with bupivacaine
Description: The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
Study NCT00556049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Study NCT00556049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Orally on days 1-14 of each 21-day treatment cycle
Study NCT04527809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-active
Description: One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
Study NCT04527809 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-sham
Description: One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
Study NCT05515926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial manipulation group, or cranial osteopathic techniques (OMM)
Description: Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue.
Study NCT05515926 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
Study NCT00257712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH9507 human growth hormone releasing hormone (GHRH)
Description: 1mg subcutaneous injection given daily for 20 weeks
Study NCT00257712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TH9507 human growth hormone releasing hormone (GHRH)
Description: 1mg subcutaneous injection given daily for 20 weeks
Study NCT00264797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (OROS-MPH)
Description: Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
Study NCT00264797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate (OROS-MPH) - Placebo
Description: Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
Study NCT01447563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulfate
Description: subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
Study NCT01447563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
Study NCT02845895 — intervention group
Intervention type: OTHER
Intervention: Caregiver dedicated
Description: Organization of nutrition screening with the help of a caregiver
Study NCT02845895 — intervention group
Intervention type: OTHER
Intervention: Classic strategy
Description: Classic organization with the training of the department team
Study NCT03249584 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OsteoCool™ RF Ablation
Description: The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
Study NCT04180007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
Study NCT00820625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation
Description: common pulmonary vein isolation procedure
Study NCT00820625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation with additional ablation of fragmented potentials
Description: common pulmonary vein isolation with additional but also common ablation of fragmented potentials
Study NCT02771548 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Study NCT02720510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: Revlimid was used with dexamethasone to treat patients with multiple myeloma
Study NCT02720510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
Study NCT02720510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone was a steroid used to treat patients with multiple myeloma.
Study NCT02720510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farydak
Description: FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
Study NCT01669538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Study NCT01669538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00406913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mupirocin ointment
Study NCT00406913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC sterilization
Study NCT00406913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC sterilization
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: during surgery soft tissues will be measured
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant insertion
Description: during surgery soft tissues will be measured
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown
Study NCT03229005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown
Study NCT02129348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Study NCT02129348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02684578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03893539 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ion Endoluminal System™
Description: The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
Study NCT00488865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular Filter Device
Description: Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
Study NCT00790959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASA!
Description: A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention.
Study NCT00790959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers.
Study NCT04211493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: whole-body-workout
Description: 20 minutes whole-body-workout
Study NCT04211493 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: whole-body-workout
Description: 20 minutes whole-body-workout
Study NCT04211493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: Electromyostimulation-intensity 5 (muscle stimulation)
Study NCT04211493 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMS-Placebo
Description: Electromyostimulation-intensity 1 (no muscle stimulation)
Study NCT00818883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.
Study NCT00818883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and hydrochlorothiazide
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
Study NCT02005536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOVAX POLIO®: Inactive Poliovirus Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT04583852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIVÍA, Ultra-Brightening Spot Micro-needle Patch
Description: a dissolving micro-needle patch, contains active ingredients